These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22876543)

  • 1. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
    Brown JJ; Zacharin MR
    J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid treatment in children with osteogenesis imperfecta.
    Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
    Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA; Peacock M
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
    Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
    J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intravenous Zolidronic acid in the treatment of pediatric osteogenesis imperfecta: a systematic review.
    Mahmoud I; Bouden S; Sahli M; Rouached L; Ben Tekaya A; Tekaya R; Saidane O; Abdelmoula L
    J Pediatr Orthop B; 2024 May; 33(3):283-289. PubMed ID: 37339526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
    Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.